Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 3.12B 2.78B 2.58B 2.35B 4.42B 295B 4.5B 31.04B 12.15B 154B 11.69B 11.44B 493B P/E 2026 *
-14.8x
P/E 2027 * 532x
Enterprise Value 2.78B 2.48B 2.31B 2.1B 3.95B 263B 4.02B 27.69B 10.84B 137B 10.43B 10.21B 439B EV / Sales 2026 *
3.83x
EV / Sales 2027 * 2.84x
Free-Float
97.31%
Yield 2026 *
-
Yield 2027 * -
1 day-1.80%
1 week-1.70%
Current month-9.69%
1 month-9.25%
3 months+23.46%
6 months-1.13%
Current year-13.30%
1 week 70.03
Extreme 70.03
76.64
1 month 70.03
Extreme 70.03
79.78
Current year 53.89
Extreme 53.89
91.53
1 year 53.89
Extreme 53.89
91.53
3 years 12.57
Extreme 12.57
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 2018-08-31
Director of Finance/CFO 64 2023-04-23
Chief Tech/Sci/R&D Officer 47 2024-11-03
Director TitleAgeSince
Chairman 48 2022-12-01
Director/Board Member 71 2019-11-30
Director/Board Member 80 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Exercice

Director

604 0.0014%
9/15/26 Exercice

Director

12,902 0.0294%
9/15/26 Exercice

Director

402 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-1.80%-1.70%-5.28%+446.92% 3.17B
+3.55%+7.01%+51.42%+105.45% 1,077B
-0.25%-1.25%+32.49%+61.48% 612B
+0.59%+4.03%+25.28%+91.54% 501B
-1.48%+1.97%+72.62%+39.59% 364B
+2.37%+7.66%+33.65%+48.87% 353B
+2.64%+6.95%+21.01%+43.85% 278B
+3.24%+6.78%+0.43%+15.71% 251B
+1.86%+6.53%+45.98%+52.77% 230B
+2.49%+6.98%+33.03%+102.67% 190B
Average +1.32%+3.63%+31.06%+100.89% 385.97B
Weighted average by Cap. +1.74%+4.11%+38.62%+72.02%

Financials

2026 *2027 *
Net sales 725M 647M 601M 547M 1.03B 68.65B 1.05B 7.22B 2.83B 35.82B 2.72B 2.66B 115B 930M 830M 772M 702M 1.32B 88.09B 1.34B 9.27B 3.63B 45.96B 3.49B 3.42B 147B
Net income -215M -192M -178M -162M -305M -20.36B -311M -2.14B -838M -10.62B -807M -790M -33.99B 9.62M 8.59M 7.98M 7.26M 13.66M 911M 13.9M 95.85M 37.5M 475M 36.1M 35.33M 1.52B
Net Debt -336M -300M -279M -254M -477M -31.85B -486M -3.35B -1.31B -16.62B -1.26B -1.24B -53.17B -476M -425M -395M -359M -675M -45.05B -687M -4.74B -1.85B -23.5B -1.78B -1.75B -75.21B
Projected Income Statement - Annual - Tarsus Pharmaceuticals, Inc.
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
26-10-15 US$70.99 -1.80% 1,398,349
26-10-14 US$72.29 +2.08% 1,166,768
26-10-13 US$70.82 -4.81% 1,632,816
26-10-12 US$74.40 +1.69% 1,463,048
26-10-09 US$73.16 +1.30% 481,753
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Tarsus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
70.99USD
Average target price
99.80USD
Spread / Average Target
+40.58%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tarsus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. TARS Stock